Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EnVivo Pharmaceuticals Announces Appointment of President and Chief Executive Officer

Published: Friday, July 12, 2013
Last Updated: Friday, July 12, 2013
Bookmark and Share
Industry leader to direct company growth, commercialization of phase 3 programs in Alzheimer’s disease and schizophrenia, and expansion of diverse CNS pipeline.

EnVivo Pharmaceuticals announced the appointment of Deborah Dunsire, M.D., as president and chief executive officer. She also joins the company’s board of directors. Dr. Dunsire, formerly president and chief executive officer of Millennium: The Takeda Oncology Company, brings more than 25 years of scientific, clinical, operational and commercial experience, and proven leadership in the biological and pharmaceutical industry.

Dr. Dunsire served as president and chief executive officer of Millennium Pharmaceuticals, Inc., now Millennium: The Takeda Oncology Company, from 2005 to 2013. During that period, she transformed the company into a biotechnology industry leader by focusing R&D, driving the development pipeline, fostering a culture of employee engagement and increasing the commercial mindset across the organization to enhance the commercial success of marketed products. The company was acquired by Takeda Pharmaceutical Company Limited in 2008 for $8.8 billion – one of the largest biotech acquisitions at that time – and became Millennium: The Takeda Oncology Company. Dr. Dunsire was the first woman appointed to Takeda’s board of directors.

“Deborah’s ability to build a fully integrated biopharmaceutical company with an award-winning culture of innovation and successfully commercialize late-stage programs while developing a leading research pipeline is unparalleled,” said Stephen Knight, M.D., chairman of the EnVivo board of directors and president of Fidelity Biosciences. “She joins EnVivo at a transformative point in the company’s evolution, as our lead product, EVP-6124, is in Phase 3 clinical trials in schizophrenia and will enter a Phase 3 clinical trial in Alzheimer’s disease later this year. We are excited to work with Deborah to build EnVivo toward global CNS leadership.

I thank Robert Weisskoff, Ph.D., for his exceptional leadership as interim chief executive officer as he resumes his prior role as a member of the company's board of directors.”

“CNS diseases, including Alzheimer’s disease and schizophrenia, take a devastating toll on patients, families and the health care system,” said Dr. Dunsire. “EnVivo’s late-stage lead product candidate and broad pipeline of promising clinical programs present a unique and compelling opportunity to develop new therapies with the potential to make a dramatic impact on patients’ lives. I am looking forward to working with the EnVivo team to purpose-build a biopharmaceutical company focused on transforming the CNS treatment landscape.”

Prior to leading Millennium, Dr. Dunsire led the Novartis U.S. Oncology Business, playing a critical role in the broad development and successful launch of a number of products. Over 10 years, she increased the North American oncology revenues from $50 million to more than $2.2 billion. She served on the U.S. Pharmaceutical Executive Committee at Novartis. Dr. Dunsire is currently a board member of Allergan, Inc., the Biotechnology Industry Organization (BIO), Museum of Science (Boston), Massachusetts General Hospital Research Advisory Council, CancerCare (New York) and the Gabrielle's Angels Foundation for Cancer Research. She has received numerous awards, including the 2001 American Cancer Society Excalibur Award, the 2009 Healthcare Businesswomen’s Association’s “Woman of the Year”, the 2011 MassBIO Innovator Award and the 2013 Boston CEO Conference Lifetime Achievement award. Dr. Dunsire received her medical degree from the University of Witwatersand, Johannesburg, South Africa.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Self-Assembling, Biomimetic Membranes May Aid Water Filtration
A synthetic membrane that self assembles and is easily produced may lead to better gas separation, water purification, drug delivery and DNA recognition, according to an international team of researchers.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
Teeth Reveal Lifetime Exposures to Metals, Toxins
Researchers have identified dental biomarkers to reveal links between early iron exposure and late life brain diseases.
An Innovative Algorithm to Decipher How Drugs Work Inside the Body
Researchers at Columbia University Medical Center (CUMC) have developed a computer algorithm that is helping scientists see how drugs produce pharmacological effects inside the body.
Uncovering the Spread of Bacteria in Pneumonia
Northwestern Medicine scientists have discovered the role a toxin produced by a pneumonia-causing bacterium plays in the spread of infection from the lungs to the bloodstream in hospitalized patients.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!